SLT recommended as first line therapy

Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Alcon acquired the historic ophthalmic instrument company in 2000